Best Response According to RECIST During First-line EGFR-Tyrosine Kinase Inhibitor Treatment Predicts Survival in EGFR mutation-positive Non-Small Cell Lung Cancer Patients
Wu, Ting-Hui, Han-Chung Hsiue, Emily, Lee, Jih-Hsiang, Lin, Chia-Chi, Liao, Wei-Yu, Ho, Chao-Chi, Shih, Jin-Yuan, Yu, Chong-Jen, Chih-Hsin Yang, JamesМова:
english
Журнал:
Clinical Lung Cancer
DOI:
10.1016/j.cllc.2018.01.005
Date:
February, 2018
Файл:
PDF, 2.31 MB
english, 2018
File converter
Більше результатів пошуку
More benefits 
